01
PATIENT-DERIVED iPS CELLS
Patient-derived iPS cells
We begin with disease information carried by patient cells, using it as a foundation for understanding human disease more faithfully.
BIOTECHNOLOGY COMPANY — KYOTO
Moving the time to treatment forward.
We use patient-derived iPS cells to understand disease mechanisms and connect those insights to gene therapy. From Kyoto, Time Biotechnologies is advancing research toward new treatment options for intractable diseases.
iPS
Starting with patient-derived cells
GENE
Pursuing fundamental treatment
KYOTO
A Kyoto-based research company
2025
Time Biotechnologies established
WHY TIME BIOTECHNOLOGIES
Time is Resource.
Our company name embodies the philosophy of viewing “Time” as the most precious resource. Converting the vast amount of time in the drug discovery process into “Cures” through technology. That is the mission of Time Biotechnologies.
Our philosophy
TECHNOLOGY
Our research approach
We connect iPS technology and gene therapy, treating disease understanding and therapeutic development as one continuous process.
02
DISEASE MODELING
Modeling and understanding disease
We derive disease-relevant cells from iPS cells and study pathological processes at the cellular level to uncover therapeutic clues.
03
GENE THERAPY
Translation into gene therapy
We connect discoveries from disease research to the development of gene therapies designed to act on underlying causes.
PIPELINE
Research pipeline
Public information on our research and development programs will be posted when available.
—
Information is currently being prepared.
Advancing research toward treatment, together.
We welcome inquiries about collaborative research, contract research, and partnerships related to iPS technology and gene therapy.